Since COVID-19, changes in the immune system, specifically increased levels of autoantibodies such as rheumatoid factor (RF), have begun to impact diagnostic testing by increasing the potential for interference in certain immunoassays.

Avoiding immunoassay interference requires blockers to be included in every immunoassay. Historically, animal-based interference blockers have been used to improve assay accuracy; however, they are susceptible to cross-reactivity with assay reagents, lot-to-lot variability, and supply shortages – as seen during the COVID-19 pandemic. Meridian’s new animal-free commercial blockers, K-BlockTM and Mouse-FREE IgG, are the next-generation solution for blocking HAMA/RF/HA that overcomes the ethical concerns and supply problems in using animal-derived blockers.

As precision medicine in oncology advances, selecting the right genomic analysis method is key to obtaining accurate and actionable insights. Whether detecting MRD, identifying mutations, or developing liquid biopsy assays, the choice between qPCR, targeted NGS, and whole-genome sequencing directly impacts clinical utility.

Speaker: Dale Clash, Strategic Marketing Manager (Molecular)

Safeguard your immunoassays with proven blocking agents

End-to-End Tailored Solutions for qPCR, Isothermal, and NGS